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In Brief
The role of Ab in cognitive impairment in
Alzheimer’s disease still remains elusive.
Yang et al. now show that Ab oligomers
bind to syntaxin 1a to impair SNARE
complex formation to inhibit exocytosis.
The resulting inhibition of
neurotransmission could therefore lead
to cognitive impairments.
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Alzheimer’s disease (AD) is closely associated with
synaptic dysfunction, and thus current treatments
often aim to stimulate neurotransmission to improve
cognitive impairment. Whereas the formation of the
soluble N-ethylmaleimide-sensitive factor attach-
ment protein receptor (SNARE) complex is essential
for synaptic transmission, the correlation between
SNAREs and AD neuropathology is unknown. Here,
we report that intracellular amyloid-b (Ab) oligomers
directly inhibit SNARE-mediated exocytosis by im-
pairing SNARE complex formation. We observe
abnormal reduction of SNARE complex levels in the
brains of APP/PS1 transgenic (TG) mice compared
to age-matched wild-types. We demonstrate that
Ab oligomers block SNARE complex assembly
through the direct interaction with a target mem-
brane (t)-SNARE syntaxin 1a in vitro. Furthermore,
the results of the in vitro single-vesicle content-
mixing assay reveal that Ab oligomers inhibit
SNARE-mediated fusion pores. Thus, our study iden-
tifies a potential molecular mechanism by which
intracellular Ab oligomers hamper SNARE-mediated
exocytosis, likely leading to AD-associated synaptic
dysfunctions.INTRODUCTION
Cognitive deficits in Alzheimer’s disease (AD) are closely asso-
ciated with synaptic dysfunction in the hippocampus and cor-
tex (Huang and Mucke, 2012; Selkoe, 2002; Sheng et al.,
2012). Stimulation of impaired synapses with acetylcholines-
terase inhibitors improves symptoms and delays disease
progression. Despite such clinical benefits, increasing acetyl-
choline (Ach) levels lacks disease-modifying properties and
becomes less effective as brain atrophy reaches severe
stages (Colovic et al., 2013; Jack et al., 2010; Kozauer and1244 Cell Reports 12, 1244–1251, August 25, 2015 ª2015 The AuthoKatz, 2013). Given that amyloid-b (Ab) oligomers are strongly
suspected to influence the progression of AD, diverse patho-
logical roles of the aggregated protein in the synapse have
been reported (Benilova et al., 2012; Haass and Selkoe,
2007; Hardy, 2009; LaFerla et al., 1995; McLean et al., 1999;
Puzzo et al., 2008; Shankar et al., 2008). However, the direct
link between abnormal Ab aggregation and synaptic dysfunc-
tion remains controversial. Thus, identification of the mecha-
nistic link may provide a key therapeutic target to effectively
treat AD.
Recent clinical investigations indicate that formation of the
soluble N-ethylmaleimide sensitive factor attachment receptors
(SNARE) complex is substantially reduced in the postmortem
brains of AD patients (Sharma et al., 2012). In neurons, vesicle
(v)-SNARE VAMP2 binds to target membrane (t)-SNAREs syn-
taxin 1a and SNAP-25 on the presynaptic membrane, whereby
assembling into a stable four-helical bundle that catalyzes
membrane fusion for exocytosis (Chen and Scheller, 2001;
Jahn and Scheller, 2006; Su¨dhof and Rothman, 2009; Weber
et al., 1998). Aberration in SNARE complex formation elicits
erratic neuronal activity, which could lead to cognitive deficits
(Corradini et al., 2009; Honer et al., 2002; Morton and Edward-
son, 2001). Interestingly, it has been suggested that misfolded
proteins cause cognitive impairments in relation to neurodegen-
eration by impairing presynaptic chaperones or directly inhibit-
ing SNARE complex formation (Burre´ et al., 2010; Choi et al.,
2013).
Remarkably, there is a strong correlation between intracellular
Ab (iAb) and the progression of AD symptoms in the early stages
of AD, indicating that iAb-induced presynaptic dysfunctionmight
be one of the pathophysiological origins of early AD (LaFerla
et al., 2007; Li et al., 2007; Parodi et al., 2010). Though Ab is nor-
mally found in the extracellular region, it is shown that Ab is often
cleaved off prematurely in the ER and Golgi. Furthermore, Ab is
trafficked back into the cytosol via the endocytotic pathway or
passive transport, leading to the accumulation of iAb (LaFerla
et al., 2007). Recently, studies have focused on the presynaptic
toxicity of Ab oligomers in relation to neuronal communication.
Genetic alterations favoring cytosolic Ab have shown to elicit
the depression of long-term potentiation and the increase of
long-term depression. Furthermore, it was previously shownrs
that exogenously administered Ab in the presynapse inhibits
neurotransmitter release from the neurons. Also, in agreement
with these observations, iAb accumulation precedes neuronal
loss and extracellular Ab deposition (Gouras et al., 2005; Moreno
et al., 2009).
In this work, we investigate the molecular mechanisms by
which synaptic transmission is affected in AD. Given that the
key clinical indication of AD is dementia, we hypothesized
that misfolded Ab might directly affect SNARE-mediated neuro-
exocytosis at the presynaptic terminal. The degree of SNARE
complex formation within the brain of APP/PS1 transgenic
(TG) mice was measured, and the in vitro binding assays
were performed to provide the molecular basis for the reduced
SNARE complex. Moreover, to investigate the effects of Ab on
the SNARE activity, we performed an in vitro single-vesicle con-
tent-mixing assay. Our results suggest that Ab oligomers
directly bind to the SNARE motif of syntaxin 1a such that
SNARE complex formation is inhibited, which might lead to
cognitive deficits in AD.
RESULTS
Reduced SNARE Complexes in APP/PS1 TG Mice
In a recent study, significant reduction of the SNARE complex
was observed within the postmortem brains of AD patients
(Sharma et al., 2012). This clinical observation indicates a
possible link between SNARE-mediated exocytosis and AD.
To determine whether the reduced SNARE complex is associ-
ated with neuropathology of AD, we compared the level of
SNARE complex formation in the cortical region of aged APP/
PS1 TG (14-month-old; male; n = 3) and age-matched wild-
type (male; n = 3) mice. The APP/PS1 TG mouse model overex-
presses human Ab, which begins to accumulate as the plaque
forms within 6 months of age and induces AD-like abnormal be-
haviors. Accumulation of human Ab in the brain is the patho-
genic culprit for AD-associated symptoms such as dramatic def-
icits in synaptic plasticity (William et al., 2012), neurobiological
damage, and cognitive deficits in learning and memory tasks
(Bornemann and Staufenbiel, 2000; German and Eisch, 2004;
Morgan, 2003). The SDS-resistant property of SNARE com-
plexes allowed us to determine the amount of complex forma-
tion using SDS-PAGE and western blot analysis. SNAP-25,
VAMP2, and syntaxin 1a antibodies were used to individually
quantify the amount of the SNARE complex in the brain homog-
enate of APP/PS1 TG and wild-type mice. Whereas there were
no apparent variations in the total amounts of SNAP-25, syn-
taxin 1a, and VAMP2, the SNARE complex bands were signifi-
cantly reduced in APP/PS1 TG mice (Figures 1A and S1A). We
note that higher-molecular-weight bands that represent oligo-
merized SNARE complexes were also detected (Kubista et al.,
2004; Sakisaka et al., 2008). The SNARE complex bands were
quantified and shown normalized to the total amount of SNAP-
25, syntaxin 1a, and VAMP2 from the boiled samples, respec-
tively, and the results show 50% decrease in the SNARE
complex formation within APP/PS1 TG mice in all three cases
(Figures 1A, right, and S1A, right). Thus, our results suggest
that aggregation of Ab may influence formation of the SNARE
complex during the development of AD.CellAbOligomers Inhibit the Formation of the SDS-Resistant
SNARE Complex
The inhibition of SNARE complex formation in APP/PS1 TGmice
suggests a possible direct interaction between Ab and SNARE
proteins. The SNARE motifs of SNAP-25, syntaxin 1a, and
VAMP2 assemble to form a four-helix bundle within the ternary
SNARE complex. Blockage or cleavage of these motifs reduces
synaptic membrane fusion and neurotransmitter release, which
may lead to cognitive deficits in AD (O’Connor et al., 1997;
Schiavo et al., 1992; Yang et al., 2010).
Here, we examined whether and how Ab affects complex for-
mation between purified recombinant SNAREs. We subjected
Ab monomers or oligomers (see Experimental Procedures for
details) to the equimolar mixture of SNAP-25, syntaxin 1a, and
VAMP2 and compared the formation of the SNARE complex in
SDS-PAGE. Remarkably, whereas monomeric Ab had no effect
on SNARE complex formation in the range of 0–0.5 mM, a signif-
icant reduction was observed in the presence of Ab oligomers
(Figure 1B). In fact, we observed only trace amounts of the
SNARE complex with 0.5 mMAb oligomers (concentrations given
in moles of monomeric Ab). Thus, our results reveal that, in
contrast to monomers, Ab oligomers have the capacity to inhibit
SNARE complex formation. These results are in coherence with
clinical observations that the development of AD correlates with
conversion of non-toxicmonomers to pathogenic oligomers (Be-
nilova et al., 2012).
Because SNARE complex formation was significantly reduced
by Ab oligomers in a minimalistic environment, a direct physical
interaction between Ab oligomers and v-SNAREs or t-SNAREs
could be anticipated. To test this idea, we performed a modified
co-floatation assay (Figure 1C) in a cell-free membrane environ-
ment (Burre´ et al., 2010). Ab oligomers were incubated with
either t-vesicles or v-vesicles, which were reconstituted with
syntaxin 1a and SNAP-25 or VAMP2 and synaptotagmin 1
(Syt1), respectively. Although Syt1 is not a SNARE protein, it is
located on the synaptic vesicle and tightly regulates Ca2+-trig-
gered synaptic exocytosis. Vesicles were then collected from
the pellets after centrifugation, followed by the dot blot analysis
using anti-beta amyloid (6E10) and anti-amyloid oligomer (A11)
antibodies (Figure 1C). We observed significant physical binding
between Ab oligomers and t-vesicles. The dot blot binding inten-
sity of t-vesicles was significantly higher than that of v-vesicles or
protein-free liposomes, thus suggesting that Ab oligomers pref-
erentially bind to either or both syntaxin 1a or SNAP-25 in the
membrane environment. Also, we confirmed the existence of
both t- and v-SNAREs in the precipitated liposomes by western
blot analysis (Figure S1B). Taken together, these results show
that Ab oligomers, but not the monomers, inhibit SNARE com-
plex formation by interacting with t-SNAREs.
Ab Is a Syntaxin 1a Binding Protein
Unless Ab oligomers interact with t-SNAREs by conformation-
specific binding, monomeric Ab could also bind to t-SNAREs.
To further dissect the molecular origin of the Ab-SNARE interac-
tion, we performed a pull-down assay employing glutathione
S-transferase (GST)-SNAP-25, -VAMP2, and -syntaxin 1a in an
attempt to specifically identify the target protein (Figure 2). The
individual GST-SNARE proteins were separately attached toReports 12, 1244–1251, August 25, 2015 ª2015 The Authors 1245
Figure 1. Ab Oligomers Inhibit SNARE Complex Formation
(A) SNARE complex assembly is reduced in aged APP/PS1 TG mice. Western blot analysis of SNARE monomers and complexes in APP/PS1 TG mice and wild-
type mice (14-month-old; n = 3 mice) was performed using anti-SNAP-25 antibody. Brain lysates were divided into two equal parts and immunoblotted without
(, left) or with (+, right) boiling prior to separation by SDS-PAGE. Page gels (12%) for unboiled () and boiled (+) sampleswere run separately but side by sidewith
markers. (+) and () membranes were aligned based on the markers. Ternary SNARE complexes were detectable only in unboiled samples. The SNARE
complexes were quantified and normalized by the amount of SNARE proteins in the boiled sample (left, representative blot; right, quantitation from five inde-
pendent blots). Data are represented as mean ± SD (**p < 0.01 by Student’s t test). See also Figure S1A.
(B) Ab oligomers inhibit formation of the SDS-resistant SNARE complex from recombinant SNAREs whereas the monomers do not. The SNARE complexes were
quantified and normalized by the total amount of SNARE proteins (left, representative SDS-PAGE gel; right, quantitation from five independent experiments). All
Ab oligomers concentrations are given as those of monomeric Ab.
(C) Schematic description of the co-floatation assay for Ab oligomers’ binding to proteoliposomes (left). The amounts of Ab bound to the individual vesicle
samples were measured by dot blot using anti-amyloid oligomer (A11) antibody or anti-beta amyloid (6E10) antibody. Representative immunoblots (middle) and
quantitation of liposome-bound proteins (right) are shown, respectively. See also Figure S1B.
In (B) and (C), the data are represented as mean ± SD (*p < 0.05, **p < 0.01, and ***p < 0.005 by Student’s t test; B: n = 5 and C: n = 3 independent experiments).the glutathione agarose beads, after which Abmonomers/oligo-
mers were added to the sample followed by thorough washing to
remove unbound proteins (Figure 2A). Both Abmonomers/oligo-1246 Cell Reports 12, 1244–1251, August 25, 2015 ª2015 The Authomers exhibited a strong affinity to syntaxin 1a whereas the
monomers show some weaker binding to SNAP-25 than the
binding to syntaxin 1a (Figures 2C–2E). In contrast, no interactionrs
Figure 2. AbMonomers and Oligomers Bind
to the SNARE Motif of Syntaxin 1a
(A) Schematics of the GST pull-down assay for
Ab’s binding to individual SNARE proteins
(B, glutathione agarose bead).
(B) The primary domain structure of syntaxin 1a.
The region corresponding to the N-terminal Habc
domain is depicted as the white bar, the SNARE
motif as the red bar, and the transmembrane (TM)
region as the black bar. SynH3 refers to the syn-
taxin 1a mutant containing only the SNARE motif.
(C) The amounts of the Abmonomers bound to the
SNARE proteins were measured by dot blot using
anti-beta amyloid antibody (6E10, top). SNARE
proteins cleaved from GST were visualized
by Coomassie blue staining after SDS-PAGE
(bottom).
(D) The amounts of Ab oligomers bound to the
SNARE proteins were measured by dot blot using
anti-amyloid oligomer antibody (A11, top). SNARE
proteins cleaved from GST were visualized by
Coomassie blue staining after SDS-PAGE
(bottom). Also, see Figure S2C for precipitation by
6E10 that verifies the existence of Ab.
(E) The dot blots of the Abmonomer and oligomers
bound to SNAREs were quantified and normalized
with respect to the Ab input. The Ab monomers and oligomers were detected by anti-beta amyloid (6E10) and anti-amyloid oligomer (A11) antibodies,
respectively. Data are represented as mean ± SD (*p < 0.05; **p < 0.01 by Student’s t test). The experiments were performed three times with independently
prepared samples.was observedwith VAMP2, which is consistent with ourmodified
co-floatation assay results.
We further investigated the Ab-binding region within syntaxin
1a by performing the pull-down experiments with truncated syn-
taxin 1a, one containing only the SNARE motif (SynH3) and the
other containing only the N-terminal Habc domain (Figure 2B).
We found that Abmonomers/oligomers bind only to SynH3, sug-
gesting that both the monomeric and oligomeric form of Ab bind
specifically to the SNAREmotif region of syntaxin 1a (Figures 2C,
2D, and S2). Notably, although only Ab oligomers display any
inhibitory effects on SNARE complex formation, both monomers
and oligomers bind to the SNARE motif region of syntaxin 1a.
Ab Oligomers Inhibit Ca2+-Triggered Content Mixing
Although the impairment of SNARE complex formation would
reduce synaptic vesicle fusion, it is critical to confirm that the
Ab-syntaxin 1a interaction induces the inhibition of SNARE-
mediated exocytosis. Thus, we performed a well-defined
in vitro single-vesicle content-mixing assay that monitors
SNARE-mediated Ca2+-triggered opening of single fusion pore
with a total internal reflection fluorescence (TIRF) microscope
(Lai et al., 2013).
Experimentally, two populations of vesicles representing the
synaptic vesicles and target membrane were prepared. The
t-vesicles, reconstituted with syntaxin 1a and SNAP-25, were in-
jected into the flow chamber and tethered on the polyethylene
glycol (PEG)-coated imaging surface. The v-vesicles, encapsu-
lated with sulforhodamine B (SRB) (20 mM) and reconstituted
with VAMP2 and Syt1, were flown into the flow chamber to allow
vesicle docking. After sufficient buffer exchange to remove any
unbound v-vesicles, 500 mM Ca2+ was injected into the flowCellcell to trigger vesicle fusion (Figure 3A). The stepwise increase
in fluorescence intensity of the v-vesicles, due to the dequench-
ing of SRB, was used to identify content mixing from individual
vesicle pairs (Figure 3A, right).
As expected, a significant decrease in content-mixing popula-
tion was observed as a function of Ab oligomers concentration.
Whereas 12% of total docked vesicle pairs displayed content
mixing, at t = 120 s, in the absence of Ab oligomers, we observed
a 10.5%, 45.8%, 72.7%, and 93.7% decrease in content-mixing
population corresponding to 1 nM, 5 nM, 10 nM, and 20 nM
treatment of Ab oligomers (concentrations given in moles of
monomeric Ab), respectively (Figure 3B). No such inhibitory
effect was observed even at higher concentrations of Ab mono-
mers, consistent with the notion that Ab oligomers are the neuro-
toxic agents (Figure 3C).
We further investigated whether Ab monomers/oligomers
affect synaptic vesicle docking by comparing the total docked
vesicle pairs at various concentrations of Ab monomers/oligo-
mers (Figure S3B). The vesicle-docking population displayed
no variations, indicating that both Ab monomers/oligomers do
not affect vesicle docking in the presence or absence of Syt1.
However, we observed a significant decrease of lipid mixing in
the presence of Ab oligomers, whereas monomers exhibited
no apparent difference (Figures S3C–S3H). Thus, our results
suggest that Ab oligomers, but not the monomers, specifically
inhibit the fusion step between docking and lipid mixing.
DISCUSSION
Ab accumulation has been associated with the cholinergic
dysfunction observed in AD, which is characterized byReports 12, 1244–1251, August 25, 2015 ª2015 The Authors 1247
Figure 3. Ab Oligomers Inhibit Ca2+-Triggered Exocytosis in the In Vitro Single-Vesicle Content-Mixing Assay
(A) Schematics of the in vitro content-mixing assay (left). A representative fluorescent intensity time trace is shown (right).
(B) The cumulative time plot of the content-mixing percentage among total docked population at various concentrations of Ab oligomers (Ca2+ injection at 10 s).
The control, without Ab oligomers, is depicted with red circles. See also Figure S3.
(C) Histogram of total content-mixing percentage during the 120-s observation period.
Data in (B) and (C) represent mean ± SD (**p < 0.01; ***p < 0.005 by Student’s t test; n = 5 independent experiments).diminished neurotransmitter release (Itoh et al., 1996; Kar et al.,
1998; Vaucher et al., 2001). However, the mechanism of Ab-me-
diated toxicity is not clearly understood. In this study, we raise
the possibility that the oligomeric form of Ab directly inhibits
SNARE-mediated exocytosis by binding to the SNARE motif of
syntaxin 1a. APP/PS1 TG mice displayed a significant decrease
in SNARE complex formation when compared with that of wild-
type mice, which is in agreement with the results from the brains
of AD patients (Sharma et al., 2012). Because APP/PS1 TGmice
are specifically engineered to overexpress Ab, but not other AD-
inducing proteins such as tau (Holcomb et al., 1998), our in vivo
data establish a possible connection between abnormal Ab and
SNARE proteins. Our in vitro experiments not only reveal that Ab
binds to syntaxin 1a but further narrow the binding region to the
SNARE motif, which forms a four-helix bundle (Poirier et al.,
1998; Sutton et al., 1998). Moreover, we demonstrate that Ab
oligomers have the capacity to inhibit SNARE-mediated exocy-
tosis bymonitoring fusion pore opening between a single-vesicle
pair with TIRF microscopy. To the contrary, the Ab monomers
failed to exhibit any inhibitory effects on SNARE complex forma-
tion or membrane fusion, despite the fact that monomers also
bind to syntaxin 1a. We speculate that steric hindrance of the
Ab monomers may not be sufficient to inhibit SNARE-mediated
exocytosis. Collectively, our results are in coherence with previ-
ous studies suggesting that iAb oligomers are the pathogens
responsible for cognitive impairment in AD (Gouras et al.,1248 Cell Reports 12, 1244–1251, August 25, 2015 ª2015 The Autho2005; LaFerla et al., 2007; Li et al., 2007; Moreno et al., 2009;
Parodi et al., 2010) and further identify the underlying molecular
mechanisms and the target protein machinery.
Interestingly, in our previous work, we found that a-synuclein
(aSyn) oligomers, which are thought to be the primal cause of
Parkinson’s disease, inhibit vesicle fusion (Choi et al., 2013). In
this case, the key interaction is between aSyn and v-SNARE,
which is somewhat different from Ab oligomers’ interaction
with t-SNARE. Although the detailed underlying molecular inter-
actions are different for aSyn and Ab, the common pathophysio-
logical theme for these two dementia-inducing proteins is their
binding to SNAREs and the inhibition of SNARE-mediated
vesicle fusion by their oligomers. Therefore, our results alto-
gether might suggest that the inhibition of SNARE-dependent
vesicle fusion is a common physiological origin shared by neuro-
degenerative diseases.
One notable observation is that Ab oligomers hinder the for-
mation of the SNARE complex, whereas having no effect on
vesicle docking. These two sets of data appear to be paradoxical
because SNARE complex formation is necessary for synaptic
vesicle docking. However, these results actually provide deep
molecular-level insights into the mechanism by which Ab oligo-
mers inhibit the SNARE function. It might be that Ab oligomers
allow only partial SNARE assembly, to the point, sufficient for
vesicle docking. In fact, the partially zipped complex, in which
only the N-terminal half is assembled, is considered a bonars
Figure 4. A Mechanistic Model for the Inhi-
bition of Ca2+-Triggered SNARE-Mediated
Exocytosis by Ab Oligomers
Normal SNARE-mediated exocytosis involves full
zippering of the SNARE complex, which induces
the fusion pore (left). A hypothetical mechanistic
model shows that Ab oligomers bind to t-SNAREs
in such a way that vesicle docking is unaffected yet
stops zippering of SNARE complex, thereby in-
hibiting pore formation (right).fide intermediate state along the SNARE-complex-formation
pathway (Kim et al., 2012; Shin et al., 2014). Thus, we speculate
that Ab oligomers botch SNARE complex formation right at this
intermediate stage by binding to the C-terminal half of the syn-
taxin 1a SNARE motif, whereby SNARE assembly is allowed
only at the N-terminal half without further progression toward
vesicle fusion (Figure 4).
SNAREproteins are constantly recycled fromsynaptic vesicles
to the plasma membrane and back to vesicles (Chen and Schel-
ler, 2001; So¨llner et al., 1993). Although we attributed the
decrease of the SNARE complex in AD-induced TG mice and
postmortem brains of AD patients to the inhibition of SNARE-
mediated vesicle fusion, the decrease could arise from other
reasons. The SDS-resistant SNARE complex represents the
cis-SNAREcomplex on the plasmamembrane. Thus, if the disas-
sembly of the cis complex to individual SNAREs by a-SNAP and
NSF on the plasma membrane is promoted or if the endocytic
pathway is accelerated by Ab oligomers, a similar reduction of
the cis-SNARE complex would be observed. However, a recent
study reported that Ab oligomers induce depletion of synaptic
vesicles (Parodi et al., 2010), suggesting that acceleration of the
endocytotic pathway is highly unlikely, warranting further investi-
gation. Also, if the expression of SNARE proteins was somehow
impaired, a similar result would be observed even in the absence
of Ab oligomers’ inhibitory effect on SNARE complex assembly.
However, the invariant total amount of SNAP-25, syntaxin 1a,
andVAMP2 inAPP/PS1TGmice suggests that this too is unlikely.
In conclusion, our study provides potential molecular mecha-
nisms of the clinical notion that presynaptic Ab inhibits synaptic
transmission. Recently, the US Food and Drug Administration
announced a new strategic plan to focus on the development
of drugs which enhance cognition of AD patients in the early
stage before overt dementia (Kozauer and Katz, 2013). Commer-
cially available AD drugs have shown that increasing levels of
Ach help daily activities of demented AD patients. Our findings
suggest an additional target for such drugs to treat AD. Blocking
the Ab binding to syntaxin 1a could help restore Ab-oligomer-
stricken SNARE-mediated exocytosis, which would help pa-
tients to regain normal cognition.EXPERIMENTAL PROCEDURES
Preparation of Ab Oligomers
The synthetic peptide wild-type Ab42 was purchased from American Peptide.
As described previously (Ahmed et al., 2010; Dahlgren et al., 2002), the Ab42
peptide was initially dissolved to 1 mM in hexafluoroisopropanol (Sigma-Al-
drich) and separated into aliquots in sterile microcentrifuge tubes. Hexafluor-
oisopropanol was removed under vacuum in a SpeedVac, and the peptide filmCellwas stored desiccated at 80C. To make oligomers, cold PBS was added to
bring the peptide to a final concentration of 10 mM and incubated at 4C for
18 hr (Ahmed et al., 2010). The size of the Ab oligomers (penta/hexamers)
was previously confirmed using size exclusion chromatography, transmission
electron microscopy, and dynamic light scattering (Ahmed et al., 2010; Bitan
et al., 2003)
In Vitro Single-Vesicle Content-Mixing Assay
After surface coating with PEGmolecules and PEG-biotin molecules (molar ra-
tio 40:1; Laysan Bio), the quartz slide was assembled into a flow chamber and
coated with streptavidin (0.2 mg/ml; Sigma-Aldrich). Following 10-min incuba-
tion at room temperature, the t-vesicles (125 mM) were immobilized on the
PEG-coated surface for 20 min. After several rounds of washing in 200 ml of
buffer, the v-vesicles (10 mM) containing 20 mM SRB were injected into the
flow chamber for the 10-min pre-docking at room temperature (25C). After
washing out the unbound v-vesicles, additional 20 min incubation was fol-
lowed by 500 mM of Ca2+ injection using motorized syringe pump. A stepwise
jump in fluorescence intensity was detected with fusion pores, due to the de-
quenching SRB. The fluorescent signals from the immobilized individual
vesicle pairs were obtained from TIRF microscope. The details of TIRF micro-
scope imaging and single-molecule data analysis have been reported in our
previous work (Diao et al., 2012).
Co-floatation Assay for Measuring the Binding Properties of Ab
Oligomers
We measured the binding properties of Ab oligomers to proteoliposomes (t-
and v-vesicles) and protein-free vesicles using a modified co-floatation assay.
Both t- and v-vesicles (200 mM) were incubated with 200 nM of Ab oligomers
for 30 min at room temperature and then centrifuged at 199,000 3 g for
30 min using airfuse centrifugation (Beckman). The amounts of vesicle-bound
Ab oligomers from pellet, compared with the initial input of Ab oligomers, were
measured by dot blot using anti-amyloid oligomer (A11) antibody (Millipore)
and anti-beta amyloid (6E10) antibody (Covance).
GST Pull-Down Assay
GST-tagged SNAREs bound to glutathione agarose bead (50 ml; 50% slurry
equilibrated in the same buffer) were mixed with Ab (1 mM) each in 500 ml
PBST (PBS containing 0.1% Triton X-100), incubated at room temperature
for 30 min with gentle agitation. After washing five times with buffer, bound
GST-tagged SNARE proteins were eluted by thrombin cleavage, followed by
dot blot and SDS-PAGE.
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